Seeking Alpha

Eli Lilly (LLY +2.7%) CEO John Lechleiter says to use caution when extrapolating the failed...

Eli Lilly (LLY +2.7%) CEO John Lechleiter says to use caution when extrapolating the failed clinical trials of Pfizer (PFE -0.5%) and Johnson & Johnson's (JNJ +0.2%) Alzheimer's candidate, bapineuzumab, to solanezumab, the one that [LLY has in its pipeline. "We've got to be very careful before we draw conclusions," Lechleiter says. There are differences between the drugs, how they bond for example, that could allow for different outcomes. The company expects to report clinical data for solanezumab later in Q3.  (Video)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector